NCT01440959View on ClinicalTrials.gov

Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

dovitinib

TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule

Trial Locations (1)

138-736

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER